June 3, 2020 / 6:39 AM / a month ago

BRIEF-Pharma Mar: TGA Grants "Provisional Approval Pathway" For Lurbinectedin In SCLC In Australia

June 3 (Reuters) - Pharma Mar SA:

* THERAPEUTIC GOODS ADMINISTRATION (TGA) GRANTS “PROVISIONAL APPROVAL PATHWAY” FOR LURBINECTEDIN IN RELAPSED SMALL CELL LUNG CANCER (SCLC) IN AUSTRALIA

* THIS DESIGNATION ALLOWS A FASTER APPROVAL OF DRUGS FOR SERIOUS CONDITIONS THAT FILL AN UNMET MEDICAL NEED

* DATA FROM PHASE II STUDY OF LURBINECTEDIN SHOWED 35% OVERALL RESPONSE RATE IN SECOND-LINE PATIENTS, AND MEDIAN OVERALL SURVIVAL OF 9.3 MONTHS Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below